NCT01433809COMPLETEDanonymous

Biomarkers in Thyroid Cancer

Sponsor

Source record

Norman Eberhardt

Phase

Source record

registry-stage

Modality

AI-normalized

RNA therapy

Target

AI-normalized

mRNA

Indication / condition

AI-normalized

Cancer of the Thyroid

Intervention

Source record

Detailed source ingestion pending.

Related intelligence directories

Indication directory: Cancer of the Thyroid Modality directory: RNA therapy Target directory: mRNA

Source & freshness

Source record

NCT ID

NCT01433809

Original source

ClinicalTrials.gov

Source last updated

Detailed source ingestion pending.

Ingested at

Jul 22, 2026

Internal sync

Jul 22, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record

View original source fields

NCT ID

NCT01433809

Title

Biomarkers in Thyroid Cancer

Sponsor

Norman Eberhardt

Status

COMPLETED

Phase

registry-stage

Condition raw

Cancer of the Thyroid, Neoplasms, Thyroid, Thyroid Adenoma, Thyroid Cancer, Thyroid Carcinoma

Condition normalized

Cancer of the Thyroid, Neoplasms, Thyroid, Thyroid Adenoma, Thyroid Cancer, Thyroid Carcinoma

Modality raw

RNA therapy

Modality normalized

RNA therapy

Target raw

mRNA

Target normalized

mRNA

Interventions

Detailed source ingestion pending

Public preview

Source record

Biomarkers in Thyroid Cancer is a registry-stage clinical asset sponsored by Norman Eberhardt in Cancer of the Thyroid, Neoplasms, Thyroid, Thyroid Adenoma, Thyroid Cancer, Thyroid Carcinoma. SEO and diligence focus: mRNA, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Early access offer

Subscribe with code FOUNDERS5 for a 5-day premium trial.

Full protocol, outcomes, eligibility, contacts and results sections

Patent/IP landscape with verified records when available

Board-ready PDF export with source provenance

Save to folders and synthesize multiple assets in premium workspace

Create account

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Biomarkers in Thyroid Cancer

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jul 28, 2026

Report code

NCT01433809-Jul 28, 2026

NCT ID

NCT01433809

Status

COMPLETED

Phase

registry-stage

Sponsor

Norman Eberhardt

Executive brief

Investment-Ready Snapshot

Source & freshness

Provenance

SourceClinicalTrials.gov

Source updatedDetailed source ingestion pending.

Internal syncJul 22, 2026

Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT01433809

Indication

Cancer of the Thyroid

Modality

RNA therapy

Target

mRNA

Intervention

Not reported

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.